Name: CORMEDIX INC (CRMD) Stock
Brand: CORMEDIX INC
Rating: 5.5 (3 reviews)

CRMD Latest News, Press Relases and Analysis

All

Press Releases

6 days ago - By: Chartmill

CorMedix Inc. (NASDAQ:CRMD) Q3 2025 Earnings: Revenue Beat Offsets EPS Miss

7 days ago - By: Chartmill

CorMedix Inc (NASDAQ:CRMD) Fulfills Key Growth Stock Criteria from The Little Book

a day ago - By: Zacks Investment Research - Mentions: ALKS SRPT

FDA Restricts Use of Sarepta's Gene Therapy, Adds Safety Warnings

5 days ago - By: The Motley Fool - Mentions: ACRX

Talphera (TLPH) Q3 2025 Earnings Call Transcript

5 days ago - By: Stocktwits

CorMedix Stock Breaks Out To 2-Month High: Analysts Reset Price Targets After Blowout Q3 And Surging DefenCath Demand

6 days ago - By: Talphera, Inc. - Mentions: TLPH

Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update

6 days ago - By: Benzinga

CorMedix Q3 Profit Soars As DefenCath Dialysis Demand Exceeds Expectations

6 days ago - By: Benzinga - Mentions: IMOS PERI PHAR MH ...

Pharming Group Posts Upbeat Q3 Results, Joins On Holding, BigBear.ai Holdings And Other Big Stocks Moving Higher On Wednesday

6 days ago - By: Stocktwits - Mentions: VFMO IWMW

Cormedix Stock Soars Pre-Market After Earnings Beat, Higher Full-Year Guidance

6 days ago - By: CorMedix, Inc.

CorMedix Inc. Reports Third Quarter 2025 Financial Results and Updates FY 2025 Guidance

7 days ago - By: Zacks Investment Research - Mentions: ALKS FOLD IMVT

Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus

7 days ago - By: Zacks Investment Research - Mentions: ALKS VRTX CRSP

CRSP Posts Narrower-Than-Expected Loss in Q3, Sales Miss Estimates

8 days ago - By: Zacks Investment Research

Wall Street Analysts Predict an 80.58% Upside in CorMedix (CRMD): Here's What You Should Know

11 days ago - By: Zacks Investment Research - Mentions: ALKS ANIP IOVA

IOVA Soars 28% on Narrower-Than-Expected Loss in Q3, Revenues Up Y/Y

11 days ago - By: Zacks Investment Research - Mentions: ALLO ALKS ANIP

Allogene Posts Narrower-Than-Expected Loss in Q3, Nil Sales

12 days ago - By: Zacks Investment Research - Mentions: ALKS ANIP RVMD

Revolution Medicines Posts Wider-Than-Expected Loss in Q3, Sales Nil

12 days ago - By: Zacks Investment Research - Mentions: ALKS JAZZ ANIP

JAZZ Beats on Q3 Earnings & Sales, Narrows '25 Sales View

12 days ago - By: Zacks Investment Research - Mentions: ALKS FOLD VTRS

Viatris Tops Q3 Earnings & Revenue Estimates, Ups '25 Guidance

13 days ago - By: Zacks Investment Research - Mentions: ALKS PRGO ANIP

Perrigo Q3 Earnings Beat, Sales Miss, Stock Falls on '25 View Cut

13 days ago - By: Zacks Investment Research - Mentions: ALKS FOLD EXAS

Amicus' Q3 Earnings Beat, Higher Product Sales Drive Y/Y Revenues

13 days ago - By: Zacks Investment Research - Mentions: BSX CHEF HNST LTH

Bet on 5 Top-Ranked Stocks With Rising P/E

14 days ago - By: Zacks Investment Research

All You Need to Know About CorMedix (CRMD) Rating Upgrade to Strong Buy

18 days ago - By: CorMedix, Inc.

CorMedix Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 12, 2025

19 days ago - By: Zacks Investment Research - Mentions: AZN MRK ANIP

MRK Beats Q3 Earnings Estimates, Narrows 2025 Sales View, Stock Down

19 days ago - By: Zacks Investment Research - Mentions: BEAM AMRN ANIP

Amarin's Q3 Earnings Lag Estimates, Revenues Beat, Stock Down

a month ago - By: CorMedix, Inc.

CorMedix Inc. Receives Innovative Technology Designation From Vizient for DefenCath

a month ago - By: Halper Sadeh LLC

Halper Sadeh LLC Encourages CorMedix Inc. Shareholders to Contact the Firm to Discuss Their Rights

a month ago - By: Talphera, Inc. - Mentions: TLPH

Talphera Announces the Appointment of Joe Todisco to Board of Directors

a month ago - By: Zacks Investment Research - Mentions: PFE AMPH

How Will DefenCath Aid CRMD's Top Line in the Upcoming Q3 Results?

a month ago - By: Stocktwits

CRMD Stock Is The Talk Of The Town Today: What’s The Latest 2025 Revenue Forecast?